Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: A SEER-Medicare Analysis
Main finding · OS (all-cause mortality)Result — go to the resultAdjusted hazard ratio 1.24 95% CI 1.01–1.53Authors' conclusion
Delays in surgery for PTC may impact OS and DSS in localized disease, prior to nodal metastasis.
Study context
- Population
- Medicare beneficiaries with papillary thyroid cancer (PTC) who underwent thyroidectomy, SEER-Medicare linked data 1999–2018; mean age 69.3 (SD+/- 11.4)
- Participants
- 8,170 beneficiaries
- Exposure
- Time to surgery: ≤90 days vs 91–180 days vs >180 days
- Outcome
- Disease-specific survival (DSS) and overall survival (OS)
Methodological detailsSEER-Medicare linked data
- SEER-Medicare linked data
Main finding
OS (all-cause mortality)
Adjusted hazard ratio
1.24
95% CI 1.01–1.53
>180 daysvs Within 90 days
aHR 1.24 (95% CI 1.01–1.53)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| OS, localized disease (summary stage)91 to 180 daysvs Within 90 daysRisk increased by 25% | 1.25 (1.05–1.51) | |
| OS, localized disease (summary stage)>180 daysvs Within 90 daysRisk increased by 61% | 1.61 (1.19–2.18) | |
| DSS mortality, localized disease>180 daysvs Within 90 daysAlmost 4 times the estimated rate | 3.51 (1.68–7.32) | |
| All-cause mortality, T2 disease>180 daysvs Within 90 daysDouble the estimated rate | 2.0 (1.1–3.3) | |
| Disease-specific mortality, T2 disease>180 daysvs Within 90 daysAlmost triple the estimated rate | 2.7 (1.05–6.8) | |
| 0.10.31310Adjusted hazard ratio (log scale) |
Original publication
Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: A SEER-Medicare Analysis. J Clin Endocrinol Metab. Published 29 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →